ALX Oncology Holdings Inc.
ALXO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.05 | 0.15 | 0.03 |
| FCF Yield | -105.71% | -74.37% | -36.41% | -26.62% |
| EV / EBITDA | -0.75 | -0.75 | -2.82 | -2.98 |
| Quality | ||||
| ROIC | -32.69% | -30.63% | -23.60% | -21.23% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.90 | 0.80 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 5.14% | 23.00% | -25.78% | 4.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 0.35 | 0.27 | 0.21 |
| Interest Coverage | -65.80 | -78.37 | -71.69 | -73.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 8.96 |
| Cash Conversion Cycle | -2,309.84 | -1,679.29 | 92.49 | -3,160.45 |